
Brandon James Essink MD CPI
Hospital Medicine/Hospitalist, Healthcare Research and Healthcare Policy, Rural Health
PI @ Velocity Clinical Research Chief Physician Officer @ Velocity Clinical Research
Join to View Full Profile
3319 N 107th StOmaha, NE 68134
Phone+1 402-933-6500
Fax+1 402-933-6501
Dr. Essink is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Brandon Essink, MD is a family medicine specialist based in Omaha, NE. He is currently the Chief Physician Officer for Velocity Clinical Research, a global clinical research company. Dr. Essink is also skilled in healthcare research, healthcare policy, and rural health. His education and training include a BS from the University of Nebraska-Lincoln, an MD from the University of Nebraska College of Medicine, and a fellowship in Vascular and Interventional Radiology at the same institution. Dr. Essink has extensive professional experience, having held positions at Avera Creighton Hospital, Bryan Medical Center, and Meridian Clinical Research, LLC. He has specialization in endoscopy, emergency medicine, clinical research, telemedicine, and rural family medicine. His publications, primarily focusing on vaccine safety and immunogenicity, have been published in leading medical journals and have received citations. Additionally, Dr. Essink has been involved in multiple clinical trials related to the safety and immunogenicity of vaccines and diverse patient conditions like Hyperhidrosis and Osteoarthritis Pain.
Education & Training
University of Nebraska Medical Center College of MedicineFellowship, Vascular and Interventional Radiology, 2003 - 2004
University of Nebraska Medical Center College of MedicineResidency, Family Medicine, 2001 - 2003
University of Nebraska College of MedicineClass of 2001
University of Nebraska-LincolnBS, 1997
Certifications & Licensure
FL State Medical License 2025 - 2028
MI State Medical License 2025 - 2028
AZ State Medical License 2024 - 2027
CO State Medical License 2024 - 2027
IA State Medical License 2020 - 2027
IN State Medical License 2024 - 2027
NJ State Medical License 2025 - 2027
American Board of Family Medicine Family Medicine- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage Stage 1 Certification Medical and Practice Management (MPM) Client/Server, LSS Data Systems, 2013-2016
- CMS Meaningful Use Stage Stage 2 Certification Medical and Practice Management (MPM) Client/Server, Medical Information Technology, Inc. (MEDITECH), 2013-2016
- CMS Meaningful Use Stage Stage 1 Certification Medical and Practice Management (MPM) Client Server, LSS Data Systems, 2013-2016
Clinical Trials
- Study of Diclofenac Capsules to Treat Osteoarthritis Pain Start of enrollment: 2011 Oct 01
- Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD) Start of enrollment: 2012 Feb 27
- Open-Label Study of Diclofenac Capsules to Treat Osteoarthritis Pain Start of enrollment: 2012 Jan 01
Publications & Presentations
PubMed
- Safety and immunogenicity of an mRNA-based RSV vaccine in seropositive children aged 12-59 months.Sabine Schnyder Ghamloush, Sue Fanning, Brandon Essink, Frank Eder, Matthew D Snape
Human Vaccines & Immunotherapeutics. 2025-12-01 - 8 citationsAn mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibiti...Boris Kandinov, Mieke Soens, Wenmei Huang, Conrado Llapur, David Ensz
Human Vaccines & Immunotherapeutics. 2025-12-01 - 3 citationsComparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open...Pedro M Folegatti, Stephanie Pepin, Cynthia Tabar, Katherine Fries, Oxana Talanova
The Lancet. Infectious Diseases. 2025-10-01
Press Mentions
mRNA Vaccine Hesitancy? Midwestern Trial Site Organization Running Multiple Competitive Phase 3 Vaccine TrialsJuly 8th, 2021
Moderna Vaccine Shows 94.1% Efficacy in a Phase 3 Clinical TrialDecember 31st, 2020
Peer-Reviewed Report on Moderna COVID-19 Vaccine PublishesDecember 30th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:

















